Autonomix Medical, Inc.
AMIX$17.40
+$13.75 (376.71%)+376.71%
OpenCash position update reveals $5.1M with sub-1M shares outstanding drives AMIX 77% premarket surge
Loading chart...
IndexN/A
Market Cap0.01B
Enterprise Value-0.00B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-2.28
P/S0.00
P/B0.48
P/C-0.23
EV/EBITDA0.25
EV/SalesN/A
EPS (ttm)-7.64
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume109.04M
Shs Outstand0.00B
Change376.71%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Expenses | $11.59M | $12.03M | $1.99M | $13.59M |
| Operating Income | $-11.59M | $-12.03M | $-1.99M | $-13.59M |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Income | $-11.41M | $-15.43M | $-1.99M | $-13.33M |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS (Basic) | $-6.46 | $-21.10 | $-0.11 | $-0.71 |
| EBITDA | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapyglobenewswire.com Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Studyglobenewswire.com Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Studyglobenewswire.com Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platformglobenewswire.com Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platformglobenewswire.com Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com Autonomix Medical wins new patent for neural sensing technologyproactiveinvestors.com
Show 12 more stories
Autonomix Medical wins new patent for neural sensing technologyproactiveinvestors.com Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grantglobenewswire.com Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grantglobenewswire.com Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Changeglobenewswire.com Autonomix Announces Reverse Stock Splitglobenewswire.com Autonomix Announces Reverse Stock Splitglobenewswire.com Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technologyglobenewswire.com Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicineglobenewswire.com Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicineglobenewswire.com Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validationglobenewswire.com Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validationglobenewswire.com Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigationglobenewswire.com
Insider Trading
No insider trades found for AMIX.
Company
About the company
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Discover more
You may be interested in